Literature DB >> 11994523

New advances in peptide receptor radionuclide therapy.

Marion de Jong1, Eric Krenning.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11994523

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  21 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

Review 2.  Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.

Authors:  David Bushnell
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

3.  Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.

Authors:  Constantin Lapa; Rudolf A Werner; Christina Bluemel; Katharina Lückerath; Andreas Schirbel; Alexander Strate; Andreas K Buck; Ken Herrmann
Journal:  EJNMMI Res       Date:  2014-08-23       Impact factor: 3.138

Review 4.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

5.  90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Authors:  Yusuf Menda; Mark T Madsen; Thomas M O'Dorisio; John J Sunderland; G Leonard Watkins; Joseph S Dillon; Sarah L Mott; Michael K Schultz; Gideon K D Zamba; David L Bushnell; M Sue O'Dorisio
Journal:  J Nucl Med       Date:  2018-03-09       Impact factor: 10.057

6.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

7.  (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India.

Authors:  Madhav Danthala; K G Kallur; G R Prashant; K Rajkumar; M Raghavendra Rao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

8.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Authors:  Amir Sabet; Khaled Ezziddin; Ulrich-Frank Pape; Karl Reichman; Torjan Haslerud; Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; James Nagarajah; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

9.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Authors:  Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M Grana; Mirco Bartolomei; Silvia M Baio; Maddalena Sansovini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-22       Impact factor: 9.236

Review 10.  Peptide receptor therapies in neuroendocrine tumors.

Authors:  L Bodei; D Ferone; C M Grana; M Cremonesi; A Signore; R A Dierckx; G Paganelli
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.